Calamos Advisors LLC Invests $886,000 in Augmedix, Inc. (NASDAQ:AUGX)

Calamos Advisors LLC bought a new stake in shares of Augmedix, Inc. (NASDAQ:AUGX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 151,494 shares of the company’s stock, valued at approximately $886,000. Calamos Advisors LLC owned 0.37% of Augmedix as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Essex Investment Management Co. LLC acquired a new stake in shares of Augmedix during the third quarter worth $2,237,000. Acadian Asset Management LLC bought a new position in shares of Augmedix in the 3rd quarter worth about $48,000. Citigroup Inc. acquired a new position in shares of Augmedix in the 3rd quarter valued at about $241,000. Barclays PLC bought a new stake in shares of Augmedix during the 3rd quarter valued at about $115,000. Finally, Vontobel Holding Ltd. grew its stake in Augmedix by 439.7% during the third quarter. Vontobel Holding Ltd. now owns 173,209 shares of the company’s stock worth $892,000 after purchasing an additional 141,113 shares during the period. Institutional investors own 87.11% of the company’s stock.

Augmedix Price Performance

Shares of NASDAQ AUGX opened at $2.99 on Monday. The company has a market capitalization of $145.73 million, a PE ratio of -6.64 and a beta of -0.16. The company has a quick ratio of 2.41, a current ratio of 2.41 and a debt-to-equity ratio of 0.66. The stock’s 50 day moving average price is $4.02 and its 200-day moving average price is $4.76. Augmedix, Inc. has a twelve month low of $2.62 and a twelve month high of $6.25.

Augmedix (NASDAQ:AUGX) last posted its quarterly earnings data on Monday, March 18th. The company reported ($0.09) earnings per share for the quarter. Augmedix had a negative return on equity of 308.50% and a negative net margin of 42.74%. The business had revenue of $12.68 million during the quarter, compared to analysts’ expectations of $12.30 million. On average, equities analysts anticipate that Augmedix, Inc. will post -0.51 EPS for the current year.

Analyst Upgrades and Downgrades

AUGX has been the subject of several recent analyst reports. Evercore ISI raised shares of Augmedix from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $4.50 to $5.00 in a research report on Tuesday, April 9th. B. Riley started coverage on shares of Augmedix in a report on Wednesday, April 3rd. They issued a “buy” rating and a $5.50 target price on the stock. Finally, Maxim Group dropped their price target on shares of Augmedix from $6.50 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, March 19th.

Insider Buying and Selling

In other Augmedix news, insider Ian Shakil sold 31,994 shares of Augmedix stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $4.06, for a total value of $129,895.64. Following the sale, the insider now owns 187,666 shares of the company’s stock, valued at $761,923.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 251,323 shares of company stock valued at $1,005,527. 10.97% of the stock is owned by insiders.

Augmedix Profile

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.